

# Assessment of Sirolimus Coated Balloon in Real World Patients

## UK-SEB 2

All comers real world patients treated with the MagicTouch Sirolimus Coated Balloon

A prospective, Multicenter, clinical registry that enrolled real world, all comers patients to measure the primary endpoint of Target Vessel Failure at 12 months.



### REAL-WORLD PATIENTS WITH DE NOVO CORONARY LESIONS IN COMPLEX COHORT

Diabetes Mellitus

36%

ACS

52%

Small Vessels


78%

Lesions ( $\geq 20$  mm)

76%

PRINCIPAL INVESTIGATOR – DR. SANDEEP BASAVARAJIAH

### Median Follow up at 640 Days\*



### Performance in Complex Settings:

Diabetes Mellitus (n= 280) vs Non Diabetes Mellitus (n=491)

TVMI – 4% vs 2%

TLR – 7% vs 7%

Small Vessels <3mm (n= 601) vs Large Vessels  $\geq 3$ mm (n= 170)

TVMI – 3% vs 2%

TLR – 5% vs 8%

### Key Takeaways

Despite of the complex patient population and lesion subsets, MagicTouch SCB demonstrated promising results with low rates of hard endpoint (cardiac death and MI), acceptable TLR and MACE. MagicTouch SCB displayed no significant difference in terms of TLR and TVMI in both DM and Non-DM group as well as in small vessel versus larger vessels demonstrating safety and efficacy in actual complex patient subsets.

\*Article published in CCI by Dr. Sandeep Basavarajaiah | [doi.org/10.1002/ccd.31244](https://doi.org/10.1002/ccd.31244)

